Effect of L-Arginine supplementation in patients with COVID-19 infection - A Randomised Controlled Trial.

Clinical Research Centre Dept of Physiology0 个研究点目标入组 74 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•AgeÃ¢â?°Â¥18 years nonpregnant patients diagnosed as COVID positive (RAT or RTPCR positive)
•Oxygen saturation while breathing on ambient room air less than 93% or on already on supplemental oxygen as determined by pulse oximetry measurement or clinically
•Less than 15 days from symptom onset for COVID-19
•Willing to take arginine/placebo as the intervention for ten days and will provide written informed consent

•Refusal to give consent
•Unable to take intervention orally for ten days
•CKD patients on hemodialysis or requiring fluid restriction as part of their management
•Patient on inotropic support at admission
•Patients requiring BIPAP (NIV) for an indication other than COVID-19 infection prior to admission
•Patients will be excluded if progression of the illness to death was imminent and inevitable within 24 hours, as determined by the treating physician.

发起方

Clinical Research Centre Dept of Physiology